JPH09512425A - 血液凝固カスケードにおける疾患を検出および治療するための方法および手段 - Google Patents
血液凝固カスケードにおける疾患を検出および治療するための方法および手段Info
- Publication number
- JPH09512425A JPH09512425A JP7527550A JP52755095A JPH09512425A JP H09512425 A JPH09512425 A JP H09512425A JP 7527550 A JP7527550 A JP 7527550A JP 52755095 A JP52755095 A JP 52755095A JP H09512425 A JPH09512425 A JP H09512425A
- Authority
- JP
- Japan
- Prior art keywords
- factor
- arg
- protein
- factor viii
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.通常は活性化プロテインCの制御下の血液凝固因子を、活性化プロテインC が不活性化することを本質的に制限する、1つ以上の該凝固因子中に少なくとも 1つの突然変異を同定することを含んで成る、抗−疑固プロテインC系において 可能性のある先天的欠陥を検出する方法。 2.活性化プロテインCが本質的に上記凝固因子を不活性化することを妨害され る、請求の範囲第1項に記載の方法。 3.凝固因子の1つが第Vまたは第VIII因子である、請求の範囲第1または第2 項に記載の方法。 4.突然変異が活性化プロテインCの開裂−部位中、またはその近くに位置する 、請求の範囲第1、2または3項に記載の方法。 5.突然変異が、核酸レベルで選択的ハイブリダイゼーション法を使用して検出 される、請求の範囲第1ないし第4項に記載の方法。 6.少なくとも1つのオリゴヌクレオチドが、上記突然変異が起こると予想され る部位に隣接する核酸の一部とハイブリダイズする、請求の範囲第5項に記載の 方法。 7.突然変異の部位を含む核酸の選択的増幅をさらに含む、請求の範囲第6項に 記載の方法。 8.増幅した核酸を分析するさらなる工程を含んで成る、請求の範囲第7項に記 載の方法。 9.第V因子中のArg306、Arg506、Arg679、Arg1765、 および第VIII因子中のArg336、Arg562、 から選択される部位に、少なくとも1つの突然変異を同定することを含んで成る 、抗凝固プロテインC系における先天的欠陥を検出する方法。 10.APC耐性を導く突然変異に隣接する、または含む核酸の一部と相補的ま たは同一の少なくとも1つの核酸、および適当な他の通常の試薬を含んで成る、 請求の範囲第1ないし第9項に記載の方法による、抗凝固プロテインC系におい て可能性のある先天的欠陥を検出するための試験キット。 11.以下のプライマー またはこれらと少なくとも70%相同的なプライマーの1つの、少なくとも特異的 にハイブリダイズする部分を含んで成る核酸の増幅を行うための請求の範囲第1 0項に記載の試験キット。 12.活性化プロテインCに耐性な、生物学的に活性な第VIIIまたは第V因子に 基づくタンパク質。 13.活性化プロテインCの開裂部位に、またはその付近に突然変異を有する、 請求の範囲第12項に記載の第VIIIまたは第V因子に基づくタンパク質。 14.突然変異がArg336、Arg562から選択される部位に位置する第VIII因 子に基づくタンパク質。 15.突然変異がArg306、Arg506、Arg679、Arg1765から選択され る部位に位置する第V因子に基づくタンパク質。 16.治療薬として使用するための、請求の範囲第12ないし第15項のいずれ か1項に記載の第VIIIまたは第V因子に基づくタンパク質。 17.血液凝固カスケードの疾患を治療するための医薬品の調製における、請求 の範囲第12ないし第15項のいずれか1項に記載の第VIIIまた は第V因子に基づくタンパク質の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT94201116.4 | 1994-04-22 | ||
EP94201116 | 1994-04-22 | ||
PCT/NL1995/000149 WO1995029259A1 (en) | 1994-04-22 | 1995-04-21 | Method and means for detecting and treating disorders in the blood coagulation cascade |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09512425A true JPH09512425A (ja) | 1997-12-16 |
JP3810080B2 JP3810080B2 (ja) | 2006-08-16 |
Family
ID=8216820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52755095A Expired - Fee Related JP3810080B2 (ja) | 1994-04-22 | 1995-04-21 | 血液凝固カスケードにおける疾患を検出および治療するための方法および手段 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6083905A (ja) |
EP (1) | EP0756638B1 (ja) |
JP (1) | JP3810080B2 (ja) |
AT (1) | ATE200225T1 (ja) |
AU (1) | AU697205B2 (ja) |
CA (1) | CA2188463C (ja) |
DE (1) | DE69520569T2 (ja) |
DK (1) | DK0756638T3 (ja) |
ES (1) | ES2157326T3 (ja) |
GR (1) | GR3036000T3 (ja) |
WO (1) | WO1995029259A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000180450A (ja) * | 1998-12-17 | 2000-06-30 | Dade Behring Marburg Gmbh | 凝固系における欠損箇所を見出す方法 |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0696325T3 (da) | 1994-02-14 | 1999-03-01 | Univ Leiden | Fremgangsmåde til screening for tilstedeværelsen af en genetisk defekt knyttet til thrombose og/eller dårligt antikoagulere |
US5705395A (en) * | 1994-11-14 | 1998-01-06 | The Scripps Research Institute | Method for diagnosis of thrombotic disorders |
US6531455B1 (en) * | 1995-03-24 | 2003-03-11 | The Regents Of The University Of California | Delivery of polynucleotides by secretory gland expression |
US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
US5874256A (en) * | 1995-06-06 | 1999-02-23 | Rijks Universiteit Leiden | Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same |
GB9604267D0 (en) * | 1996-02-29 | 1996-05-01 | Royal Infirmary Of Edinburgh N | Mutation assay |
PT947585E (pt) | 1998-03-19 | 2001-11-30 | Instrumentation Lab Spa | Metodo in vitro melhorado, kits e reagentes para a peaquisa de defeitos de coagulacao sanguinea |
JP4676585B2 (ja) * | 1999-12-24 | 2011-04-27 | 一般財団法人化学及血清療法研究所 | 血液凝固異常に基づく疾患の治療・予防用医薬組成物 |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
AU2002248329B2 (en) * | 2001-01-12 | 2007-06-28 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
CN1596125A (zh) * | 2001-11-09 | 2005-03-16 | 诺和诺德医疗保健公司 | 包括因子ⅶ多肽和因子ⅴ多肽的药物组合物 |
US7125846B2 (en) * | 2001-11-09 | 2006-10-24 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides |
US7067541B2 (en) | 2003-06-04 | 2006-06-27 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
US7375100B2 (en) | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
EP1734941A2 (en) | 2004-03-25 | 2006-12-27 | The Feinstein Institute for Medical Research | Neural tourniquet |
WO2006027111A1 (en) * | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Modified coagulation factor viii with enhanced stability |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
DE602005025020D1 (de) | 2004-12-27 | 2011-01-05 | The Feinstein Inst Medical Res | Behandlung von entzündlichen erkrankungen durch el |
AU2006311730B2 (en) * | 2005-11-09 | 2010-12-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Factor V Leiden mutant gene |
WO2008059043A2 (en) * | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Combination of coagulation factor viii with apc-resistant factor v |
WO2008059009A2 (en) * | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Factor v mutants for hemostasis in hemophilia |
EP2081589B1 (en) * | 2006-11-16 | 2010-10-06 | Crucell Holland B.V. | Complementation of factor xi deficiency by factor v mutants |
US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
EP2247303A4 (en) * | 2007-12-20 | 2011-12-07 | Univ Queensland | HEMOSTASE MODULATING COMPOSITIONS AND USES THEREFOR |
WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
AU2009316801C1 (en) | 2008-11-18 | 2015-12-24 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflammatory stimulation |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8612002B2 (en) | 2009-12-23 | 2013-12-17 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
ITFI20110084A1 (it) * | 2011-04-22 | 2012-10-23 | Kedrion Spa | Nuovo processo per la preparazione di un concentrato di fv virus inattivato a partire da plasma umano, scalabile a livello industriale. |
CN103619405B (zh) | 2011-05-09 | 2015-11-25 | 赛博恩特医疗器械公司 | 用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活 |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
EP3405255A4 (en) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS |
CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
IL298193B2 (en) | 2020-05-21 | 2024-01-01 | Feinstein Institutes For Medical Research | Systems and methods for stimulating the vagus nerve |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5451521A (en) * | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
-
1995
- 1995-04-21 DE DE69520569T patent/DE69520569T2/de not_active Expired - Lifetime
- 1995-04-21 WO PCT/NL1995/000149 patent/WO1995029259A1/en active IP Right Grant
- 1995-04-21 EP EP95916845A patent/EP0756638B1/en not_active Expired - Lifetime
- 1995-04-21 AT AT95916845T patent/ATE200225T1/de not_active IP Right Cessation
- 1995-04-21 DK DK95916845T patent/DK0756638T3/da active
- 1995-04-21 CA CA002188463A patent/CA2188463C/en not_active Expired - Fee Related
- 1995-04-21 AU AU23194/95A patent/AU697205B2/en not_active Ceased
- 1995-04-21 US US08/722,240 patent/US6083905A/en not_active Expired - Fee Related
- 1995-04-21 ES ES95916845T patent/ES2157326T3/es not_active Expired - Lifetime
- 1995-04-21 JP JP52755095A patent/JP3810080B2/ja not_active Expired - Fee Related
-
2001
- 2001-06-06 GR GR20010400853T patent/GR3036000T3/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000180450A (ja) * | 1998-12-17 | 2000-06-30 | Dade Behring Marburg Gmbh | 凝固系における欠損箇所を見出す方法 |
Also Published As
Publication number | Publication date |
---|---|
DK0756638T3 (da) | 2001-07-23 |
DE69520569D1 (de) | 2001-05-10 |
ES2157326T3 (es) | 2001-08-16 |
EP0756638B1 (en) | 2001-04-04 |
US6083905A (en) | 2000-07-04 |
GR3036000T3 (en) | 2001-09-28 |
DE69520569T2 (de) | 2001-10-04 |
JP3810080B2 (ja) | 2006-08-16 |
WO1995029259A1 (en) | 1995-11-02 |
CA2188463C (en) | 2007-12-11 |
EP0756638A1 (en) | 1997-02-05 |
ATE200225T1 (de) | 2001-04-15 |
CA2188463A1 (en) | 1995-11-02 |
AU2319495A (en) | 1995-11-16 |
AU697205B2 (en) | 1998-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09512425A (ja) | 血液凝固カスケードにおける疾患を検出および治療するための方法および手段 | |
JP7015810B2 (ja) | 第viii因子組成物、ならびに組成物の作製方法および用途 | |
Kane et al. | Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders | |
Lee et al. | The molecular basis of haemophilia B | |
CA1341395C (en) | Preparation of functional human factor viii | |
Dahlbäck | New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gin mutation in factor V as a pathogenic risk factor for venous thrombosis | |
EP1359222B1 (en) | Hybrid human/porcine factor VIII | |
US5654147A (en) | Method of hybridization using oligonucleotide probes | |
JPH10117787A (ja) | ファクターvii活性を有する蛋白質の製造方法 | |
TW201900184A (zh) | 用於血友病b基因療法之編碼具有增強表現的重組fix變異體之病毒載體 | |
Takahashi et al. | Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease | |
Gaucher et al. | Identification of two point mutations in the von Willebrand factor gene of three families with the ‘Normandy’variant of von Willebrand disease | |
Dahlback | Factor V and protein S as cofactors to activated protein C | |
Poort et al. | Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder | |
Bovill et al. | Protein CVermont: symptomatic type II protein C deficiency associated with two GLA domain mutations | |
Mccgraw et al. | Structure and function of factor IX: defects in haemophilia B | |
Standen et al. | Factor XIII ABristol 1: detection of a nonsense mutation (Arg171→+ stop codon) in factor XIII A subunit deficiency | |
Hillarp et al. | Activated protein C resistance as a basis for venous thrombosis | |
Dahlbäck | Molecular genetics of venous thromboembolism | |
Blajchman et al. | Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity | |
Fu et al. | Identification of three F5 gene mutations associated with inherited coagulation factor V deficiency in two Chinese pedigrees | |
LARNER | The molecular pathology of haemophilia | |
Shinozawa et al. | Molecular characterization of 3 factor V mutations, R2174L, V1813M, and a 5-bp deletion, that cause factor V deficiency | |
US20080312143A1 (en) | Modified Cdna for High Expression Levels of Factor VIII and Its Derivatives | |
EP0648268A1 (en) | Therapeutic fragments of von willebrand factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050322 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050615 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050922 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060516 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060523 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100602 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100602 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110602 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |